whether ALL patients with coronary artery disease should take a beta-blocker

December 2012

You'll hear controversy about whether ALL patients with coronary artery disease should take a beta-blocker.

We were all taught that most of these patients should get a beta-blocker INDEFINITELY...especially if they've had a heart attack.

Older trials show that beta-blockers reduce mortality in the first couple of years after an MI...but this is being extrapolated to all patients with coronary artery disease (CAD).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Cardiology whether ALL patients with coronary artery disease should take a beta-blocker
Anticoagulants Xarelto (rivaroxaban) will be used to TREAT venous thromboembolism
Anticoagulants more about bleeding with Pradaxa (dabigatran)
Gastroenterology Linzess (lin-ZESS, linaclotide) for irritable bowel syndrome with constipation or chronic constipation in adults
Corticosteroids Rayos, a new delayed-release prednisone designed for evening dosing
Vaccines Prevnar 13 vaccine will be used in certain ADULTS
Vaccines New CDC guidelines will bring more focus on proper vaccine storage
Diabetes debate about whether diabetes patients who don't use insulin benefit from monitoring their blood glucose
Respiratory & Allergy Tudorza Pressair (TU-door-za, aclidinium), a new inhaled bronchodilator for COPD
Gout rev up promotion of Uloric (febuxostat) for managing gout
Compounding new oversight of pharmacy compounding
Interactions PPIs with methotrexate can lead to methotrexate toxicity
Practice enjoy the holiday letter from our staff

whether ALL patients with coronary artery disease should take a beta-blocker

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents